- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00442117
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)
A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Mild Persistent and Moderate Persistent Asthmatic Patients
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be 12 years of age or older of either gender, who (and their parent/guardian if the subject is under the age of 20) must demonstrate their willingness to sign and write informed consent.
- Subjects must have had a history of asthma for at least 6 months.
- The subject must be diagnosed mild persistent or moderate persistent asthma and his/her FEV1 must be >= 60% of predicted normal at both the Screening and Baseline visits, when short-acting inhaled beta agonists have been withheld for at least six hours and long-acting inhaled beta agonists have been withheld for at least 12 hours.
- Subjects must demonstrate an increase in absolute FEV1 of >= 12%, with an absolute volume increase of at least 200 mL, after reversibility testing at the Screening visit, or historically within the past 12 months; Subjects without documented absolute FEV1 of >= 12% in reversibility test within the past 12 months need to demonstrate a positive result in Methacholine challenge test.
If Subjects with ICS treatment have been using ICS on a daily basis for at least 4 weeks prior to Screening. For the two weeks prior to Screening, subjects must have been on a stable regimen of ICS. Each ICS dose is shown in following:
- Flunisolide between 1000 to 2000 mcg/day
- Budesonide between 400 to 800 mcg/day
- Triamcinolone acetonide between 600 to 1600 mcg/day
- Beclomethasone Dipropionate between 252 to 840 mcg/day
- Fluticasone propionate between 200 to 500 mcg/day
- Women of childbearing potential must have a negative urine (hCG) pregnancy test on the day of randomization (Baseline visit).
- Women of childbearing potential (includes women who are less than 1 year postmenopausal) must be using or agree to use an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation) if they become sexually active.
- Subjects must understand and be able to adhere to visit schedules and enter information in a daily diary.
Exclusion Criteria:
- Female subjects who are pregnant, breast-feeding, or are pre-menarcheal.
- Subjects who are heavy smokers (more than 10 pack years) or who smoked within previous 6 months.
- Subjects who have required daily or alternate day oral corticosteroid treatment for more than a total of 14 days during the 3 months immediately prior to the Screening visit, and/or subjects who have required a course of systemic corticosteroids within the previous month.
- Subjects who used Leukotriene modifiers within 2 weeks of screening.
- Subjects who took immunosuppressive agents within the previous 3 months.
- Subjects who use daily nebulized ß2-adrenergic agonists.
- Subjects who have had either an asthma exacerbation or a clinically relevant change in asthma medication within the last 4 weeks.
- Subjects who have been admitted to the hospital for asthma control within the previous 3 months or have needed emergency service for asthma more than once within the previous 6 months.
- Subjects who have required ventilator support for respiratory failure secondary to their asthma within the last 5 years.
- Subjects who have used any investigational drug in the 30 days prior to Baseline, or subjects who have been treated with any investigational antibody for asthma in the 90 days prior to Baseline.
- Subjects who are allergic or have had an idiosyncratic reaction to corticosteroids.
- Subjects with evidence of clinically significant oropharyngeal candidiasis at Screening or Baseline.
- Subjects with any clinically significant disorder of the cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or immunologic system, or respiratory disease other than asthma (e.g. COPD), or any other disorder which may interfere with the study evaluations or affect subject safety.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MF-DPI
MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day)
|
MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
Other Names:
|
Active Comparator: BUD-DPI
Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day)
|
Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Change of Forced Expiratory Volume in One Second (FEV1) From Baseline to Week 12.
Time Frame: Baseline and Week 12
|
FEV1 (forced expiratory volume in one second) measurement at the Baseline visit was compared to the FEV1 measurement during the last visit at Week 12.
The mean percent change was calculated.
|
Baseline and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Change of FVC (Forced Vital Capacity) From Baseline to Week 12.
Time Frame: Baseline and Week 12
|
The FVC measurement at the baseline was compared to the FVC measurement during the last visit at Week 12.
The mean percent change was calculated.
|
Baseline and Week 12
|
Mean Percent Change of Forced Expiratory Flow (FEF) at (25-75% Interval) From Baseline to Week 12.
Time Frame: Baseline and Week 12
|
The FEF (25-75%) measurement at the baseline was compared to the FEF (25-75%) measurement during the last visit at Week 12.
The mean percent change was calculated.
|
Baseline and Week 12
|
Mean Percent Change of AM PEFR (Peak Exploratory Flow Rate) From Baseline to Week 12.
Time Frame: Baseline and Week 12
|
The AM PEFR measurement at the Baseline visit was compared to the AM PEFR measurement during the last visit at Week 12.
The mean percent change was calculated.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Budesonide
- Mometasone Furoate
Other Study ID Numbers
- P04880
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on mometasone furoate dry powder inhaler
-
Organon and CoCompleted
-
Esfam Biotech Pty LtdNot yet recruiting
-
Vectura LimitedUCB PharmaCompleted
-
Orion Corporation, Orion PharmaCompletedPulmonary Disease, Chronic Obstructive | AsthmaUnited Kingdom, Finland
-
GB002, Inc.Not yet recruitingPulmonary Arterial HypertensionUnited States
-
GB002, Inc.RecruitingPulmonary Arterial HypertensionUnited States, Spain, Israel, Korea, Republic of, Netherlands, France, Singapore, United Kingdom, Lithuania, Australia, Latvia, Argentina, Portugal, Greece, Czechia, Puerto Rico, Belgium, Italy, Poland, Romania, Serbia, Austria, Chile, Denma... and more
-
GB002, Inc., a wholly owned subsidiary of Gossamer...RecruitingPulmonary Arterial HypertensionUnited States, Australia, Spain, Czechia, France, Germany, United Kingdom, Belgium
-
GB002, Inc., a wholly owned subsidiary of Gossamer...CompletedPulmonary Arterial HypertensionUnited States, United Kingdom
-
GB002, Inc., a wholly owned subsidiary of Gossamer...Worldwide Clinical Trials; Pulmokine Inc.Completed